Status:

COMPLETED

The Effect of the TENA SmartCare Change Indicator on Care Efficiency and Skin Health in Long Term Care Facilities

Lead Sponsor:

Essity Hygiene and Health AB

Conditions:

Urinary Incontinence

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this post market clinical investigation is to demonstrate the performance and safety of the TENA SmartCare Change Indicator when used in a nursing home setting.

Detailed Description

The TENA SmartCare Change Indicator is intended for use on individuals suffering from Urinary Incontinence who are cared for in a nursing home environment, by one or more professional caregivers. The ...

Eligibility Criteria

Inclusion

  • Subject has urinary incontinence managed with incontinence products with tapes, belted or pull up incontinence product type (products for moderate to heavy incontinence).
  • Subject is a permanent (intended length of stay four months or longer) resident of the nursing home.
  • Subject is unable to consistently communicate toileting needs.
  • Subject is unable to successfully toilet and change the pad without assistance.
  • Subject is using or is willing to use TENA Slip (Stretch) TENA Flex (Belted) and TENA Pants (Underwear) absorbing products for the study.
  • Subject has a waist size appropriate to the available sizes of incontinence products.
  • Subject is willing and able to provide informed consent to participate or if unable to provide consent have a legal representative who is willing and able to provide informed consent on behalf of the subject.
  • Subject is part of a continence care regimen, defined as "check and change", using any method.
  • If applicable, subject is to be on a stable regimen of medications for urinary incontinence
  • Subject is over 18 years of age.

Exclusion

  • Subject has frequent (daily) faecal incontinence in the pad or having severe problems with faecal incontinence as determined by the investigator.
  • Subject has severe incontinence product related skin problems, as defined by the GLOBIAD categorization 2B (skin loss \& infection).
  • Subject has any type of indwelling or external urinary catheter(s).
  • Subject is anuric.
  • Subject is managed using another automated or digital health technology incontinence management device.
  • Subject has responsive behaviors of sufficient severity, in the opinion of the care staff, to make participation impractical.
  • Subject has any other condition that makes participation in the clinical investigation inappropriate, as judged by investigator.
  • Subject has a life expectancy of fewer than 3 months or be receiving palliative or terminal care.
  • Subject has participated in an investigational study of a drug, biologic, or device within 30 days prior to entering the clinical investigation or planned during the clinical investigation.
  • Subject is dependent on either alcohol or recreational drugs.

Key Trial Info

Start Date :

October 7 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2024

Estimated Enrollment :

108 Patients enrolled

Trial Details

Trial ID

NCT05247047

Start Date

October 7 2022

End Date

January 30 2024

Last Update

August 11 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Alberta

Edmonton, Alberta, Canada, T6G 2P4

2

Hochschule Niederrhein University of Applied Sciences

Krefeld, Germany, 47805